#India #financial results #Mumbai #revenue growth #Piramal Pharma

Piramal Pharma Limited: Strong Q2 and H1 FY27 Performance Overview

Piramal Pharma Limited, a prominent player in the global pharmaceutical and health sector, reported its latest financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2027. Starting with substantial revenue growth, the company showcased its resilience and adaptability in a competitive market.

Financial Highlights

In Q2 FY27, Piramal Pharma registered revenue from operations amounting to ₹2,617 crores, reflecting a remarkable growth of 28% compared to ₹2,044 crores in Q2 FY26. For H1 FY27, total revenue reached ₹4,887 crores, marking a 23% increase over the previous year's ₹3,977 crores. This growth can be attributed to the robust performance across its three primary business segments: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH).

Revenue by Segment

• - CDMO: This segment showed a significant growth of 36% year-on-year (YoY) in Q2, contributing ₹1,424 crores to total revenue and ₹2,611 crores for the half-year, which is a growth of 28% YoY.
• - CHG: Achieving a 32% growth YoY in Q2, CHG's revenue amounted to ₹849 crores, reflecting the company’s leadership in the market, especially in the inhalation anesthesia sector.
• - PCH: The Consumer Healthcare sector maintained stability with a 14% growth, contributing to consistent sales through strong Power Brands and e-commerce enhancements.

Profitability Improvements

The firm also noted a substantial uplift in profitability metrics, highlighted by a 72% increase in Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) in Q2 FY27. The EBITDA margin rose to 14.7%, a notable increase from 11% in the corresponding quarter last year. This improvement is driven by optimized operational efficiencies, better capacity utilization, and strategic cost management.

Enhanced Customer Engagement

In addition to its financial results, Piramal Pharma demonstrated solid customer engagement with 110 customer audits conducted in H1 FY27, and the addition of 22 new clients. These initiatives underline the company's commitment to quality and regulatory compliance, evidenced by successfully passing 12 regulatory inspections without receiving any official actions indicated from the FDA.

Chairperson Nandini Piramal remarked, "The team has displayed exemplary discipline and execution despite challenges, allowing us to capture opportunities effectively and sustain momentum across all business verticals."

Outlook and Future Growth

Buoyed by the strong H1 outcomes, Piramal Pharma has revised its fiscal outlook, now forecasting a growth in revenue by 19% to 20% for FY27, alongside considerable profit margin expansions. The company continues to prioritize innovation and efficiency, which signals a promising future, particularly as the healthcare sector recovers and grows post-pandemic.

Conclusion

Piramal Pharma Limited's results for Q2 and H1 FY27 reflect a company in strong health, with impressive revenue growth and expanding energy. The upcoming conference call, scheduled for October 28, 2026, will provide further insights into their strategies and projections moving forward. With encouraging indications for the second half of the fiscal year, stakeholders can look forward to a robust performance from Piramal Pharma in the near future.